CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY

CenterBook Partners LP acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 512,367 shares of the company’s stock, valued at approximately $5,149,000. CenterBook Partners LP owned about 0.52% of ARS Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in ARS Pharmaceuticals by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock worth $35,178,000 after purchasing an additional 237,630 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of ARS Pharmaceuticals by 106.1% during the third quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock worth $31,125,000 after buying an additional 1,594,447 shares during the period. Profund Advisors LLC grew its holdings in shares of ARS Pharmaceuticals by 54.1% during the third quarter. Profund Advisors LLC now owns 26,330 shares of the company’s stock valued at $265,000 after buying an additional 9,242 shares during the last quarter. American Assets Inc. purchased a new stake in shares of ARS Pharmaceuticals during the third quarter valued at $553,000. Finally, Principal Financial Group Inc. increased its position in shares of ARS Pharmaceuticals by 38.7% in the 3rd quarter. Principal Financial Group Inc. now owns 76,884 shares of the company’s stock valued at $773,000 after acquiring an additional 21,438 shares during the period. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $9.45 on Thursday. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51. The firm has a market cap of $934.13 million, a price-to-earnings ratio of -11.67 and a beta of 0.79. The company has a 50 day moving average price of $10.59 and a 200-day moving average price of $10.72. ARS Pharmaceuticals, Inc. has a 1-year low of $6.66 and a 1-year high of $18.90.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Roth Mkm assumed coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Zacks Research downgraded ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 27th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.67.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.